Bristol-Myers Hepatitis C Therapy With Sovaldi Meets Study Goals

Bristol-Myers Hepatitis C Therapy With Sovaldi Meets Study Goals Bristol has been focusing on the hepatitis C treatment—called daclatasvir—in combination with Sovaldi following the U.S. Food and Drug Administration's rejection of its new drug application in November for daclatasvir in … Continue reading